Laura van't Veer
MD
Leader, Breast Oncology Program
👥Biography 个人简介
Laura van't Veer developed MammaPrint — the 70-gene breast cancer prognostic signature that now guides chemotherapy decisions for early-stage breast cancer. The MINDACT trial validated MammaPrint's ability to identify patients who can safely forgo adjuvant chemotherapy, sparing thousands of patients annually from unnecessary treatment. Her pioneering work demonstrated how genomic profiling could personalize breast cancer management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Laura van't Veer 的研究动态
Follow Laura van't Veer's research updates
留下邮箱，当我们发布与 Laura van't Veer（UCSF Helen Diller Family Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment